These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9871445)

  • 1. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN
    Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN
    Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
    Blanchet PJ; Metman LV; Mouradian MM; Chase TN
    Mov Disord; 1996 Sep; 11(5):580-1. PubMed ID: 8866502
    [No Abstract]   [Full Text] [Related]  

  • 5. NMDA antagonists as Parkinson's disease therapy: disseminating the evidence.
    Majláth Z; Vécsei L
    Neurodegener Dis Manag; 2014; 4(1):23-30. PubMed ID: 24640976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
    Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman LV; Chase TN; Bonuccelli U
    Mov Disord; 2001 May; 16(3):515-20. PubMed ID: 11391748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
    Elahi B; Phielipp N; Chen R
    Can J Neurol Sci; 2012 Jul; 39(4):465-72. PubMed ID: 22728853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
    Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E
    Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
    Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
    Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
    Blanchet PJ; Papa SM; Metman LV; Mouradian MM; Chase TN
    Neurosci Biobehav Rev; 1997 Jul; 21(4):447-53. PubMed ID: 9195602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic drugs in Parkinson's disease.
    Lange KW; Riederer P
    Life Sci; 1994; 55(25-26):2067-75. PubMed ID: 7997066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.
    Calon F; Rajput AH; Hornykiewicz O; Bédard PJ; Di Paolo T
    Neurobiol Dis; 2003 Dec; 14(3):404-16. PubMed ID: 14678757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
    Papa SM; Chase TN
    Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
    Chase TN; Oh JD; Konitsiotis S
    J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease.
    Růzicka E; Streitová H; Jech R; Kanovský P; Roth J; Rektorová I; Mecír P; Hortová H; Bares M; Hejduková B; Rektor I
    J Neural Transm (Vienna); 2000; 107(11):1297-306. PubMed ID: 11145005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of glutamate antagonists in the therapy of Parkinson's disease.
    Blandini F; Greenamyre JT
    Fundam Clin Pharmacol; 1998; 12(1):4-12. PubMed ID: 9523179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
    Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
    Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
    Danysz W; Parsons CG; Kornhuber J; Schmidt WJ; Quack G
    Neurosci Biobehav Rev; 1997 Jul; 21(4):455-68. PubMed ID: 9195603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.